茚達特羅

茚達特羅
臨床資料
商品名（英語：Drug nomenclature）	Onbrez Breezhaler、Arcapta Neohaler
AHFS/Drugs.com	國際藥品名稱
核准狀況	歐 EMA: yes; 美 DailyMed: Indacaterol;
懷孕分級	澳: B3 ; ;
給藥途徑	吸入
ATC碼	R03AC18 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）;
識別資訊
	IUPAC命名法 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; ;
CAS號	312753-06-3
PubChem CID	6433117;
IUPHAR/BPS	7455;
ChemSpider	5293751 ;
UNII	8OR09251MQ;
KEGG	D09318 ;
ChEBI	CHEBI:68575 ;
ChEMBL	ChEMBL1095777 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID90185198 ;
ECHA InfoCard	100.218.577
化學資訊
化學式	C24H28N2O3
摩爾質量	392.50 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4;
	InChI InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 ; Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N ;

茚達特羅（INN：indacaterol）是諾華公司開發的超長效β-腎上腺素受體激動劑（英語：Long-acting beta-adrenoceptor agonist）。^[5]與相關藥物福莫特羅和沙美特羅不同，它每天只需服用一次。^[6]該藥物僅被許可用於治療慢性阻塞性肺病（迄今為止缺乏哮喘患者的長期數據）。它可通過乾粉吸入器（英語：Dry-powder inhaler）以氣霧劑形式輸送。

醫療用途

考科藍合作組織的一項綜述發現，茚達特羅在改善慢性阻塞性肺病患者的肺功能方面效果至少與每日兩次長效β2受體激動劑相當。^[7]

歷史

它於2009年11月30日獲得歐洲藥品管理局批准，商品名為Onbrez Breezhaler，^[8]。它也於2011年7月1日獲得美國食品和藥物管理局批准，商品名為Arcapta Neohaler。^[9]^[10]2016年，諾華將Arcapta Neohaler的美國商業權授權給Sunovion（英語：Sunovion）製藥。^[11]

參考資料

^ Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011. DailyMed. 1 April 2020 [14 June 2021]. （原始內容存檔於2021-06-15）.
^ Onbrez Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始內容存檔於2021-01-28）.
^ Oslif Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始內容存檔於2021-01-28）.
^ Hirobriz Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始內容存檔於2021-01-28）.
^ Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. July 2005, 14 (7): 775–83. PMID 16022567. S2CID 11930383. doi:10.1517/13543784.14.7.775.
^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. May 2007, 29 (5): 871–8. PMID 17251236. doi:10.1183/09031936.00060006  .
^ Geake, James B. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Reviews. 2015, 1 (3): CD010139. PMC 6464646  . PMID 25575340. doi:10.1002/14651858.CD010139.pub2.
^ European Public Assessment Report for Onbrez Breezhaler 互聯網檔案館的存檔，存檔日期2010-01-16.
^ FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease (新聞稿). U.S. Food and Drug Administration. 2011-07-01 [2011-07-02]. （原始內容存檔於2011-07-03）.
^ Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383. U.S. Food and Drug Administration. 13 August 2013 [14 June 2021]. （原始內容存檔於2021-04-07）.
^ Faulkner, Sarah. Sunovion, Novartis ink licensing deal for inhaled COPD drugs. Drug Delivery Business. 22 December 2016 [2024-05-23]. （原始內容存檔於2021-10-31）.

[1] Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011. DailyMed. 1 April 2020 [14 June 2021]. （原始內容存檔於2021-06-15）.

[2] Onbrez Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始內容存檔於2021-01-28）.

[3] Oslif Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始內容存檔於2021-01-28）.

[4] Hirobriz Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始內容存檔於2021-01-28）.

[pmid16022567-5] Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. July 2005, 14 (7): 775–83. PMID 16022567. S2CID 11930383. doi:10.1517/13543784.14.7.775.

[pmid17251236-6] Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. May 2007, 29 (5): 871–8. PMID 17251236. doi:10.1183/09031936.00060006  .

[7] Geake, James B. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Reviews. 2015, 1 (3): CD010139. PMC 6464646  . PMID 25575340. doi:10.1002/14651858.CD010139.pub2.

[8] European Public Assessment Report for Onbrez Breezhaler 互聯網檔案館的存檔，存檔日期2010-01-16.

[9] FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease (新聞稿). U.S. Food and Drug Administration. 2011-07-01 [2011-07-02]. （原始內容存檔於2011-07-03）.

[10] Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383. U.S. Food and Drug Administration. 13 August 2013 [14 June 2021]. （原始內容存檔於2021-04-07）.

[11] Faulkner, Sarah. Sunovion, Novartis ink licensing deal for inhaled COPD drugs. Drug Delivery Business. 22 December 2016 [2024-05-23]. （原始內容存檔於2021-10-31）.

[5]

[6]

[2]

[3]

[4]

[1]

[7]

[8]

[9]

[10]

[11]